Palladium-mediated ketolization
US-2018155361-A1 · Jun 7, 2018 · US
Macrocyclic compound and uses thereof
US10954249B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10954249-B2 |
| Application number | US-201816500924-A |
| Country | US |
| Kind code | B2 |
| Filing date | Apr 3, 2018 |
| Priority date | Apr 5, 2017 |
| Publication date | Mar 23, 2021 |
| Grant date | Mar 23, 2021 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention provides novel Compound (1) having tumor vascular remodeling effect and/or anti-CAF (Cancer Associated Fibroblasts) activity, or a pharmaceutically acceptable salt thereof, optionally in a pharmaceutically acceptable and medical uses thereof.
First claim
Opening claim text (preview).
What is claimed is: 1. A compound selected from the group consisting of: and salts thereof. 2. The compound of claim 1 , wherein the compound is of Formula (D-5), or a salt thereof. 3. The compound of claim 1 , wherein the compound is of Formula (D-4), or a salt thereof.
Assignees
Inventors
Classifications
against CD28 or CD152 · CPC title
against proteinaceous materials, e.g. enzymes, hormones, lymphokines · CPC title
Antineoplastic agents · CPC title
- C07D493/22Primary
in which the condensed system contains four or more hetero rings · CPC title
having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10954249B2 cover?
- The present invention provides novel Compound (1) having tumor vascular remodeling effect and/or anti-CAF (Cancer Associated Fibroblasts) activity, or a pharmaceutically acceptable salt thereof, optionally in a pharmaceutically acceptable and medical uses thereof.
- Who is the assignee on this patent?
- Harvard College, Eisai R&D Man Co Ltd
- What technology area does this patent fall under?
- Primary CPC classification C07D493/22. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Mar 23 2021 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 12 related publications on this page (citations in our corpus or others sharing the same primary CPC).